MRNA - Spark Newswire

2 minute read

FDA
News

Moderna Reports First Patient Dosed In Phase 1/2 Study In Its Quadrivalent Seasonal Flu mRNA Vaccine

Today, 6:50 AM

mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and

MRNA

2 minute read

Jim Cramer Says Moderna Stock Is ‘Too High At This Point’

By Madhukumar Warrier

Today, 6:50 AM

CNBC host Jim Cramer said that Moderna Inc.’s (NASDAQ: MRNA) stock is “too high at this point” and the biotechnology company’s crucial test is whether it can offer personalized cancer vaccines in time to offset the decline in COVID-19 vaccine sales.

MRNA

2 minute read

Understanding Moderna’s Unusual Options Activity

By Benzinga Insights

Today, 6:50 AM

On Tuesday, shares of Moderna (NASDAQ:MRNA) saw unusual options activity. After the option alert, the stock price moved down to $232.87.

MRNA

1 minute read

South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters

By Vandana Singh

Today, 6:50 AM

South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the country.

AZN

1 minute read

News
Rumors

S. Korea in Talks with mRNA Vaccine Makers, Including Pfizer and Moderna to Make up to 1B Doses

By Charles Gross

Today, 6:50 AM

-Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-skorea-talks-with-mrna-vaccine-makers-make-up-1-bln-doses-govt-2021-07-05/

BNTX

1 minute read

German Health Minister Says People Who Had First Dose Of AstraZeneca COVID-19 Vaccine Should Have An mRNA Vaccine As Their Second Dose

By Benzinga Newsdesk

Today, 6:50 AM

-Reuters

AZN

2 minute read

What’s Going On With Johnson & Johnson (JNJ) Stock Today?

By Madhukumar Warrier

Today, 6:50 AM

Shares of Johnson & Johnson (NYSE: JNJ) rose 0.7% in the regular trading session on Thursday and were trading slightly higher in the market session on Friday.

BNTX

2 minute read

Unusual Options Activity Insight: Moderna

By Benzinga Insights

Today, 6:50 AM

On Thursday, shares of Moderna (NASDAQ:MRNA) saw unusual options activity. After the option alert, the stock price moved down to $230.69.

MRNA

1 minute read

Moderna Announces Recipharm Site In France Now Manufacturing COVID-19 Vaccine

By Benzinga Newsdesk

Today, 6:50 AM

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO),

MRNA